Lbp Am Sa Has $11.68 Million Position in Amgen Inc. (NASDAQ:AMGN)

LBP AM SA cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,480 shares of the medical research company's stock after selling 1,507 shares during the period. LBP AM SA's holdings in Amgen were worth $11,677,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Capital World Investors lifted its position in shares of Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after acquiring an additional 6,029,058 shares in the last quarter. Norges Bank purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $1,541,991,000. GAMMA Investing LLC lifted its position in Amgen by 43,573.5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after buying an additional 3,653,205 shares in the last quarter. Capital International Investors lifted its position in Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Amgen by 52.7% in the 4th quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company's stock worth $858,020,000 after buying an additional 1,135,884 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AMGN. Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $305.00 target price on shares of Amgen in a research note on Tuesday, June 24th. Finally, UBS Group reiterated a "neutral" rating and issued a $315.00 target price (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $307.82.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.76% of the stock is owned by insiders.

Amgen Trading Down 1.7%

NASDAQ AMGN traded down $5.10 during trading on Friday, reaching $295.27. 1,619,752 shares of the stock traded hands, compared to its average volume of 2,845,152. The firm has a market cap of $158.77 billion, a price-to-earnings ratio of 26.94, a price-to-earnings-growth ratio of 2.72 and a beta of 0.49. The stock's 50-day moving average price is $283.56 and its 200 day moving average price is $287.97. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The business's revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.96 earnings per share. Analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.